Uterine tumour resembling an ovarian sex cord tumour

J Sutak, D Lazic, J E Cullimore

CASE REPORT

Endometrial stromal sarcomas account for 0.25% of all uterine malignancies. These tumours were originally divided into low grade and high grade stromal sarcomas, but the recent World Health Organisation classification (2003) recognises low grade stromal sarcoma and undifferentiated endometrial sarcoma. Low grade sarcomas may exhibit other forms of differentiation, including smooth muscle and sex cord differentiation. In the latter form, the tumour contains epithelial-like or sex cord-like elements often with epithelioid appearance, arranged in nests, cords, trabeculae, solid, or tubular structures. If this element predominates, the tumour is considered to be a uterine tumour resembling ovarian sex cord tumour, and may cause diagnostic difficulties. This case report describes the histological and immunohistochemical features of a uterine stromal sarcoma showing exclusively a pattern reminiscent of ovarian sex cord tumour.

Clinical presentation

A 74 year old woman presented with recurrent postmenopausal bleeding. Initially, atypical hyperplasia of the endometrium was diagnosed and she was treated with progestogens. However, her bleeding recurred and further endometrial sampling revealed a poorly differentiated carcinoma. A subsequent total abdominal hysterectomy with bilateral salpingo-oophorectomy was performed.

Materials and methods

The surgical specimen was fixed in 10% neutral buffered formalin. Sections for histological examination were routinely processed in paraffin wax and stained by the avidin–biotin complex method using a Labvision (Freemont, California, USA) autostainer. The following antibodies were used: Cam5.2 (Becton-Dickinson, Oxford, UK), AE1/AE3 (Dako, Ely, Cambridgeshire, UK), 34β E12 (Novocastra, Newcastle on Tyne, UK), anti-CK18 (Novocastra), anti-vimentin (Dako), anti-S100 (Dako), anti-desmin (Novocastra), anti-actin (Novocastra), anti-inhibin (Dako), anti-CD10 (Novocastra), anti-oestrogen (clone 6F11; Novocastra), anti-CD99 (Dako), anti-calretinin (Novocastra), and anti-WT1 (Santa-Cruz Biotechnology, Santa Cruz, California, USA).

Immunostaining was carried out using appropriate positive controls.

Macroscopic findings

The surgical specimen was a total hysterectomy specimen consisting of the uterine body (65 x 65 x 45 mm) and a separate cervix (30 x 35 x 20 mm). There were also separate bilateral adnexa: one ovary (25 x 15 x 20 mm) with attached tube (40 x 5 x 5 mm) and the other ovary (25 x 25 x 15 mm) with attached tube (40 x 5 x 5 mm).

In the right uterine cornu there was a fairly well circumscribed tumour mass, 22 mm in diameter, deeply invading the myometrium and protruding into the uterine cavity. The tumour cut surface was soft, white, and partly haemorrhagic (Fig 1).

Both adnexa were unremarkable. Representative sections from the tumour were taken and were examined microscopically.

Microscopic findings

The luminal aspect of the tumour was lined with attenuated endometrial epithelium.

The tumour mass displayed fairly well circumscribed borders, and the entire tumour showed a pattern reminiscent of an ovarian sex cord stromal tumour. The tumour cells were arranged into sheets with the formation of cords, trabeculae, rosettes, and pseudotubular structures (Fig 2).

The cells showed epithelial-like features with vesicular nuclei and prominent nucleoli. There was no necrosis within the tumour. The mitotic activity was moderate: seven
mitoses/10 high power fields. Extensive intratumorous lymphovascular invasion was noted.

Immunohistochemistry revealed that the tumour cells were negative for epithelial markers—Cam5.2, CK18, 34βE12, and AE1/AE3—and also for S100 and smooth muscle markers—desmin and smooth muscle actin. Staining for inhibin, progesterone, and calretinin was also negative. The tumour showed widespread positivity for vimentin, focal nuclear positivity for WT-1, and focal membrane positivity for CD99 and CD10 (fig 3).

DISCUSSION

UTROSCT was first described by Clement and Scully in 1976. They described 14 endometrial stromal sarcomas with epithelial-like differentiation of a different pattern.2 These tumours are thought to be a rare and unique variant of uterine stromal sarcoma and pose problems in diagnosis and nomenclature. Histologically, they closely resemble ovarian sex cord tumours. The neoplastic cells grow predominantly in an epithelial-like pattern and form anastomosing trabeculae and cords. Some of these tumours can be accompanied by focal rhabdoid3 and smooth muscle4,5 differentiation. They were originally divided into two groups, namely: group I, made up of tumours with predominant endometrial stromal differentiation and only focal differentiation into sex cord-like elements; and group II, composed predominantly or exclusively of a pattern reminiscent of ovarian sex cord tumour. Recently, the designation UTROSCT has been reserved for group II tumours only.7

UTROSCTs are generally round, well circumscribed masses, up to 10 cm in diameter, that may be submucosal, intramural, or subserosal. The cut surface is soft yellow or tan. Clinically, these tumours have a low malignant potential.8,9

In their original article, Clement and Scully found that on follow up eight patients with tumours composed predominantly or exclusively of sex cord-like elements were clinically free of disease four months to seven years postoperatively.7 However, because there are few reported cases and little or limited follow up in most cases, other authors think that UTROSCT should be regarded as unpredictable, with potential for recurrence or possibly even metastasis, particularly if they are invasive, until longer follow up with larger numbers of cases becomes available.5

The pathological features of the present tumour were similar to those of previously reported cases of UTROSCT, so that the tumour was diagnosed as such. However, the immunohistochemical features of the tumour were somewhat inconsistent with the previously described cases. It was negative for inhibin, progesterone, calretinin, and smooth muscle actin, which have been described previously as positive in these tumours.3,9 The tumour showed strong diffuse vimentin positivity, and focal CD10, CD99, and WT1 positivity.

“Focal positivity for CD10, CD99, and WT-1 is well described in these tumours but none of these markers is specific.”

The differential diagnosis included epithelioid leiomyoma, epithelioid leiomyosarcoma, epithelial neoplasm, mixed müllerian tumour, and metastatic ovarian sex cord tumour. These tumours could be ruled out mostly on morphology, with the help of immunohistochemistry. The tumour cells showed no evidence of smooth muscle differentiation microscopically—they did not have abundant eosinophilic cytoplasm and the tumour cells were also negative for smooth muscle markers. Epithelial and mixed müllerian tumours were ruled out because of the complete lack of glandular differentiation, and the absence of biphasic epithelial mesenchymal differentiation, which is characteristic of müllerian tumours. The tumour cells were uniform and showed no evidence of pleomorphism or atypia. In addition, the cells showed no immunoreactivity for epithelial markers.

Both ovaries were unremarkable and did not contain “primary” ovarian sex cord tumour.

The hysterectomy was performed in September 2003, and to date (15 months later) our patient has been clinically free of disease.

The diagnosis of endometrial stromal tumour resembling ovarian sex cord tumour is largely based on the highly characteristic microscopic appearances described above. Focal positivity for CD10, CD99, and WT-1 is well described in these tumours but none of these markers is specific.9

Familiarity with this tumour by gynaecologists and pathologists is essential to avoid misdiagnosis, because the correct diagnosis of this neoplasm is important in patient management.
Take home messages

- This case report describes a 74 year old woman who was diagnosed with uterine sarcoma resembling ovarian sex cord tumour
- The morphological and histological features of the present tumour were similar to those of previously reported cases, although the immunohistochemical features were somewhat inconsistent with previously described cases.
- Gynaecologists and pathologists should be aware of this tumour because the correct diagnosis is important in patient management.

Authors’ affiliations

J Sutak, D Lazic, Department of Pathology, Great Western Hospital, Marlborough Road, Swindon SN3 6BB, UK
J E Cullimore, Department of Obstetrics and Gynaecology, Great Western Hospital
Correspondence to: Dr D Lazic, Department of Pathology, Great Western Hospital, Swindon and Marlborough NHS Trust, Marlborough Road, Swindon SN3 6BB, UK; Darko.Lazic@smnhst.swest.nhs.uk

Accepted for publication 18 January 2005

REFERENCES

Uterine tumour resembling an ovarian sex cord tumour

J Sutak, D Lazic and J E Cullimore

J Clin Pathol 2005 58: 888-890
doi: 10.1136/jcp.2004.022616

Updated information and services can be found at:
http://jcp.bmj.com/content/58/8/888

These include:

References
This article cites 9 articles, 0 of which you can access for free at:
http://jcp.bmj.com/content/58/8/888#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/